Market LIVE
Published markets; coverage varies by country
Product profile · United States

ARYMO ER

 ·  Patent Litigation & Settlement History ↓

IngredientMORPHINE SULFATE
Application typeNDA
Application208603
Product002
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
Strength30MG
Approval date2017-01-09
Marketing statusDiscontinued
Status event—
ApplicantZYLA
Product source

Current GenericRadar decision

Year2018
SelectionDISCONTINUED
ReviewFINAL
Anchor typeDISCONTINUATION
Anchor date2018-09-28
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA—
Status event2018-09-28

Egalet SEC 8-K: manufacturing/promotion discontinued effective 2018-09-28; FDA notified and Orange Book discontinued-list transfer requested. Consistent with original Discontinued status. Evidence limits: see source report.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
90444022033-07-01DP/U U-1556———
[GNR_US204_50] Not used as a canonical patent anchor for the DISCONTINUED decision; does not establish complete claim verification.
———
90444022033-07-01DP/U U-1556———
Not used as a canonical patent anchor for the DISCONTINUED decision; does not establish complete claim verification.
———
95498992033-07-01DP/U U-1556———
[GNR_US204_50] Not used as a canonical patent anchor for the DISCONTINUED decision; does not establish complete claim verification.
———
95498992033-07-01DP/U U-1556———
Not used as a canonical patent anchor for the DISCONTINUED decision; does not establish complete claim verification.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · CURRENT_SNAPSHOT_NO_RECORD · Historical coverage: NOT_COMPLETE

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
074862 / 002FINAL_APPROVAL · FINAL_APPROVED1998-07-07—RHODES PHARMACEUTICALS LPNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
075295 / 002FINAL_APPROVAL · FINAL_APPROVED1998-10-28—STRIDES PHARMA INTERNATIONAL AGNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
076412 / 002FINAL_APPROVAL · FINAL_APPROVED2003-07-31—SPECGX LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
076720 / 002FINAL_APPROVAL · FINAL_APPROVED2005-12-23—NESHER PHARMACEUTICALS USA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
200824 / 002FINAL_APPROVAL · FINAL_APPROVED2011-10-18—RISING PHARMA HOLDINGS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
078761 / 002FINAL_APPROVAL · FINAL_APPROVED2012-05-11—SUN PHARMACEUTICAL INDUSTRIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
203849 / 002FINAL_APPROVAL · FINAL_APPROVED2015-04-06—ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
203602 / 002FINAL_APPROVAL · FINAL_APPROVED2015-12-16—NOVEL LABORATORIES INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
091357 / 002FINAL_APPROVAL · FINAL_APPROVED2016-06-23—EPIC PHARMA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
205634 / 002FINAL_APPROVAL · FINAL_APPROVED2016-08-25—SUN PHARMACEUTICAL INDUSTRIES INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
205386 / 002FINAL_APPROVAL · FINAL_APPROVED2016-10-28—DR REDDYS LABORATORIES SANEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 11 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
074862 / 002RHODES PHARMACEUTICALS LPFINAL_APPROVAL · FINAL_APPROVED1998-07-07 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
075295 / 002STRIDES PHARMA INTERNATIONAL AGFINAL_APPROVAL · FINAL_APPROVED1998-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
076412 / 002SPECGX LLCFINAL_APPROVAL · FINAL_APPROVED2003-07-31 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
076720 / 002NESHER PHARMACEUTICALS USA LLCFINAL_APPROVAL · FINAL_APPROVED2005-12-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
200824 / 002RISING PHARMA HOLDINGS INCFINAL_APPROVAL · FINAL_APPROVED2011-10-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
078761 / 002SUN PHARMACEUTICAL INDUSTRIES LTDFINAL_APPROVAL · FINAL_APPROVED2012-05-11 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
203849 / 002ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2015-04-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
203602 / 002NOVEL LABORATORIES INCFINAL_APPROVAL · FINAL_APPROVED2015-12-16 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
091357 / 002EPIC PHARMA LLCFINAL_APPROVAL · FINAL_APPROVED2016-06-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
205634 / 002SUN PHARMACEUTICAL INDUSTRIES INCFINAL_APPROVAL · FINAL_APPROVED2016-08-25 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
205386 / 002DR REDDYS LABORATORIES SAFINAL_APPROVAL · FINAL_APPROVED2016-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (2)
TypeDateRoleBasisSource
PATENT2033-07-01FTO_TAILNot used as a canonical patent anchor for the DISCONTINUED decision; does not establish complete claim verification.Source
PATENT2033-07-01FTO_TAILNot used as a canonical patent anchor for the DISCONTINUED decision; does not establish complete claim verification.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.